These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25622899)

  • 1. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
    Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
    Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas.
    Imperiale A; Moussallieh FM; Sebag F; Brunaud L; Barlier A; Elbayed K; Bachellier P; Goichot B; Pacak K; Namer IJ; Taïeb D
    PLoS One; 2013; 8(11):e80539. PubMed ID: 24312232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
    Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
    Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
    Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
    Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
    Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
    Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
    Vicha A; Musil Z; Pacak K
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
    Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
    Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.
    Rao JU; Engelke UF; Sweep FC; Pacak K; Kusters B; Goudswaard AG; Hermus AR; Mensenkamp AR; Eisenhofer G; Qin N; Richter S; Kunst HP; Timmers HJ; Wevers RA
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E214-22. PubMed ID: 25459911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
    Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
    Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.
    Lendvai N; Pawlosky R; Bullova P; Eisenhofer G; Patocs A; Veech RL; Pacak K
    Endocrinology; 2014 Jan; 155(1):27-32. PubMed ID: 24189137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.
    Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M
    Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
    Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
    J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
    Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
    Vicha A; Taieb D; Pacak K
    Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline
    Santi R; Rapizzi E; Canu L; Ercolino T; Baroni G; Fucci R; Costa G; Mannelli M; Nesi G
    Anticancer Res; 2017 Feb; 37(2):805-812. PubMed ID: 28179334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.
    Persu A; Lannoy N; Maiter D; Mendola A; Montigny P; Oriot P; Vinck W; Garin P; Hamoir M; Vikkula M
    Horm Metab Res; 2012 May; 44(5):349-53. PubMed ID: 22566194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.